Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remdesivir in moderate COVID-19
NCT04560231Phase 1Unknown
- Sponsor
- Lahore General Hospital
- Start
- Jun 2020
- Primary completion
- Nov 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of remdesivir in coronavirus disease 2019 (COVID-19), sponsored by Lahore General Hospital. Primary endpoint: Clinical response after administration at 10 days. Status: unknown.
02
Drugs
remdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04560231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04560231.